We value your privacy
We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.
Clinical Trials
62
47 active
Approvals
2
Total approvals
Agencies
Regulatory bodies
Founded
2000
Active, not recruiting
47
75.8%
Approved For Marketing
1
1.6%
Completed
3
4.8%
Recruiting
Terminated
7
11.3%
Withdrawn
EMA
European Medicines Agency
CIMA_AEMPS
Spanish Agency for Medicines and Medical Devices
- Two real-world evidence studies from Spain and Italy demonstrate Pepaxti's effectiveness in heavily pretreated relapsed or refractory multiple myeloma patients at the IMS Annual Meeting. - The Italian study reports a 47% overall response rate in patients who had received multiple prior therapies, including novel immunotherapies targeting BCMA and GPRC5D. - Both studies confirm Pepaxti's favorable safety profile in real-world clinical settings, providing crucial evidence for treatment decisions outside controlled trial environments. - The data underscore growing physician confidence in Pepaxti's clinical utility, particularly in later lines of therapy where treatment options are limited.
